利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

298 条记录 (耗时 0.068 秒)

    Stable iron oligosaccharide compound
    1.
    发明授权
    Stable iron oligosaccharide compound 有权

    公开(公告)号：US10414831B2

    公开(公告)日：2019-09-17

    申请号：US16178943

    申请日：2018-11-02

    申请人： Pharmacosmos Holding A/S

    发明人： Hans Andreasen

    IPC分类号： C08B37/02 ,  C07H3/06 ,  A61K31/721 ,  A61K47/26

    摘要： The invention relates to an iron oligosaccharide compound with improved stability comprising a hydrogenated oligosaccharide in stable association with ferric oxyhydroxide, the content of dimes saccharide in said hydrogenated oligosaccharide being 2.9% by weight or less, based on the total weight of the hydrogenated oligosaccharide. In further aspects is provided a process for preparing said compound as well as the use of said compound for preparation of a composition for treatment of iron deficiency anaemia.

    Therapy for treatment or prevention of conditions associated with bleeding or hypocoagulation
    2.
    发明授权
    Therapy for treatment or prevention of conditions associated with bleeding or hypocoagulation 有权

    公开(公告)号：US10407488B2

    公开(公告)日：2019-09-10

    申请号：US15034385

    申请日：2014-11-04

    申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ,  THE SCRIPPS RESEARCH INSTITUTE

    发明人： John H. Griffin ,  Laurent Mosnier ,  Annette Von Drygalski ,  Andrew Gale

    IPC分类号： A61K38/36 ,  C07K14/745 ,  A61K38/48 ,  A61K45/06

    摘要： The present application generally relates to methods to prevent or treat bleeding and/or hypocoagulation in an individual in need thereof, and compositions for use in such methods. The methods comprise administration of FVa, preferably an APC resistant FVa (such as superFVa), alone or in combination with FVIIa, preferably rhFVIIa (such as NovoSeven® or another FVIIa having enhanced activity or half-life). When administered in combination, FVa and FVIIa elicit a synergistic benefit when used to treat or prevent bleeding or hypocoagulation in subjects in need thereof, e.g., subjects with a genetic disorder such as hemophilia or an acquired bleeding disorder or other condition associated with bleeding or hypocoagulation such as hemorrhagic stroke or shock, trauma, surgery or dysmenorrhea or individuals who produce inhibitory antibodies against procoagulants such as FVIII or FIX or who have been administered an overdose of an anticoagulant drug such as a direct Xa or direct thrombin inhibitor or a Novel Oral Anti-Coagulant (NOAC) or demonstrate unexplained bleeding. Also, the invention relates to the use of a superFVa alone or in combination with FVIIa or other procoagulant or prohemostatic agent to prevent, treat or reverse APC-associated bleeding, e.g., as the result of APC overproduction (such as through serious injury and/or hemorrhagic shock) or APC or other anticoagulant therapy, e.g., in the treatment of inflammatory disorders or sepsis disease.

    Antibodies to IL-6 and use thereof
    5.
    发明授权
    Antibodies to IL-6 and use thereof 有权

    公开(公告)号：US10344086B2

    公开(公告)日：2019-07-09

    申请号：US15700374

    申请日：2017-09-11

    申请人： ALDERBIO HOLDINGS LLC

    发明人： Leon F. Garcia-Martinez ,  Anne Elisabeth Carvalho Jensen ,  Katie Anderson ,  Benjamin H. Dutzar ,  Ethan W. Ojala ,  Brian R. Kovacevich ,  John A. Latham ,  Jeffrey T. L. Smith

    IPC分类号： C12P21/02 ,  C07K16/24 ,  C12N9/64 ,  C12N9/60 ,  C12N15/81 ,  A61K39/00

    摘要： The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6. These antibodies may bind at least one of soluble IL-6, cell surface expressed IL-6, IL-6/IL-6R and/or prevent the association of IL-6 and IL-6R, the association of IL-6/IL-6R and gp130 and or the formation of IL-6/IL-6R/gp130 multimers and thereby inhibit a biological effect associated with any of the foregoing.

    Screening assays to identify compounds which modulate T1R associated taste modalities which eliminate false positives
    7.
    发明授权
    Screening assays to identify compounds which modulate T1R associated taste modalities which eliminate false positives 有权

    公开(公告)号：US10281467B2

    公开(公告)日：2019-05-07

    申请号：US15724407

    申请日：2017-10-04

    申请人： SENOMYX, INC.

    发明人： Guy Servant ,  Nicole Servant

    IPC分类号： G01N33/566

    摘要： This invention relates to assays which screen for compounds that modulate taste elicited by the T1R2/T1R3 sweet taste receptor which include a novel counter screen to eliminate false positives. In addition, the invention contemplates assays which screen for compounds that modulate taste elicited by the T1R1/T1R3 umami taste receptor which include a novel counter screen to eliminate false positives. Preferably the assays are conducted in high throughput format thereby enabling the screening of many hundreds of different compounds whereby the counter screen significantly improves assay efficiency. Further, the invention relates to the use of the compounds identified in the subject screening assays to modulate T1R associated taste perception.